AKR1C3 Aldo Keto Reductase Family 1 Member C3
AKR1C3 belongs to a superfamily of NAD(P)H-linked oxidoreductases that reduces aldehydes and ketones to their corresponding primary and secondary alcohols, plays a role in carbonyl metabolism of a broad range of endogenous and exogenous substrates, and has proposed physiologic roles in metabolizing xenobiotics and chemical carcinogens.
AKR1C3 overexpression has been documented in a number of treatment-resistant and difficult-to-treat cancers including: hepatocellular carcinomas (HCC), castrate-resistant prostate cancer (CRPC), and T-cell acute lymphoblastic leukemia (T-ALL). AKR1C3 is highly expressed in up to 15 solid and liquid tumors.
Individualized patient selection by staining for AKR1C3 overexpression by immunohistochemistry can be performed based on tumor biopsies or circulating tumor cells to identify patients with other tumor types most likely to respond to treatment with OBI-3424. This approach may offer the possibility of a streamlined clinical development strategy.